Experimental obesity drug targets appetite through amylin, offering potential alternative to GLP-1 therapies
New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept. 28–Oct. 2), and published in The Lancet Diabetes & Endocrinology shows that weekly injections of the new amylin-based obesity drug petrelintide can enable those treated to
<p>New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept. 28–Oct. 2), and published in The Lancet Diabetes & Endocrinology shows that weekly injections of the new amylin-based obesity drug petrelintide can enable those treated to</p>